Botulinum Toxin Type A Blockade of the Sphenopalatine Ganglion in Treatment-refractory Chronic Migraine

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

170

Participants

Timeline

Start Date

October 1, 2019

Primary Completion Date

June 13, 2025

Study Completion Date

June 30, 2026

Conditions
Migraine Disorders
Interventions
DRUG

Botulinum toxin type A

Botulinum toxin 25 Allergan units in 0.5 ml Sodium Chloride (NaCl) 0.9 % Braun. Two injections, one in each side of the face, and targeting the sphenopalatine ganglion.

DRUG

placebo

0.5 ml Sodium Chloride (NaCl) 0.9% Braun. Two injections, one in each side of the face, and targeting the sphenopalatine ganglion.

Trial Locations (4)

Unknown

Haukeland University Hospital, department of Neurology, Bergen

Nordland Hospital, department of Neurology, Bodø

Nevroklinikken Universitetet i Oslo, Oslo Universitetssykehus HF, Oslo

St Olavs Hospital, Trondheim University Hospital, Trondheim

All Listed Sponsors
collaborator

Norwegian University of Science and Technology

OTHER

collaborator

Oslo University Hospital

OTHER

collaborator

Haukeland University Hospital

OTHER

collaborator

Nordlandssykehuset HF

OTHER

lead

St. Olavs Hospital

OTHER

NCT04069897 - Botulinum Toxin Type A Blockade of the Sphenopalatine Ganglion in Treatment-refractory Chronic Migraine | Biotech Hunter | Biotech Hunter